Patrícia Godinho

Ms. Patrícia Godinho

LAQV-REQUIMTE, Department of Chemistry, University of Aveiro
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PGPatrícia Godinho
Patrícia Godinho
Raquel SoengasRaquel Soengas
Raquel Soengas
Vera Lucia Marques Da SilvaVera Lucia Marques Da Silva
Vera Lucia Marques Da Silva
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread all over the world, creating a devastating socio-economic impact. Even though protective vaccines are starting to be administered, an effective antiviral agent for the prevention and treatment of COVID-19 is not available yet. Moreover, since new and deadly CoVs can emerge at any time with the potential of becoming pandemics, the development of therapeutic agents against potentially deadly CoVs is a research area of much current interest. In the search for anti-coronaviral drugs, researchers soon turned their heads towards glycosylated flavonoids. Glycosyl flavonoids, widespread in the plant kingdom, have received a lot of attention due to their widely recognized antioxidant, anti-inflammatory, neuroprotective, anticarcinogenic, antidiabetic, antimicrobial, and antiviral properties together with their capacity to modulate key cellular functions. The wide range of biological activities displayed by glycosyl flavonoids, along with their low toxicity, make them ideal candidates for drug development. In this review, we examine and discuss the up-to-date developments on glycosyl flavonoids as evidence-based natural sources of antivirals against coronaviruses and their potential role in the management of COVID-19.

21 February 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
PGPatrícia Godinho
Patrícia Godinho
PPPaula Pérez-Ramos
Paula Pérez-Ramos
YGYaiza Gabasa
Yaiza Gabasa
ECEnmanuel Cornielle
Enmanuel Cornielle
Sara GonzálezSara González
Sara González
Artur M. S. SilvaArtur M. S. Silva
Artur M. S. Silva
Introduction/Objectives: Nosocomial infections caused by S. aureus and S. epidermidis resistant strains are an important cause of morbidity and mortality worldwide. Due to the increasing rate of resistance to conventional antibiotics, the discovery of new antibiotic drugs is crucial to keep pace with the evolution of these pathogenic bacterial species. Methods: The 3-nitro-2H-chromene moiety is present in several compounds with potent antibacterial activity; based on these previous studies, we report herein the synthesis of 20 new 2-aryl-3-nitro-2H-chromene derivatives and the evaluation of their antibacterial potential in vitro. Results: Mono-halogenated nitrochromenes showed moderate anti-staphylococcal activity with MIC values of 8–32 μg/mL, whereas tri-halogenated 3-nitro-2H-chromenes displayed potent anti-staphylococcal activities with MIC values of 1–8 μg/mL. Notably, 2-(4-bromophenyl)-6-bromo-8-chloro-3-nitro-2H-chromene 5s was the best antibacterial agent in the series against multidrug-resistant strains of S. aureus and S. epidermidis with MIC values of 4 μg/mL and 1–4 μg/mL, respectively. Conclusions: nitrochromene 5s shows a good safety profile, so it can be considered as a lead for further development.